Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has announced the approval of its ‘Liraglutide Injection’ for marketing in China as a treatment for type 2 diabetes, with the potential for aiding weight control and cardiovascular health. Developed by the company, Liraglutide is recognized by various diabetic treatment guidelines and the drug’s market in China is expected to grow significantly by 2030. The company has optimized the product’s complex production process, ensuring high-quality manufacturing and is also working on a new drug, semaglutide, which is in clinical phase III trials.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
